Angela Lamarca, Lead of NET HPB and NET Medical Oncologist an Fundación Jiménez Diaz University Hospital. Chair of ESMO Communication Commitee. Lead of EORTC NET WG shared a post on X:
“Also at ASCO 2026.
CamrelizumabRivoceranibTace against Tace.
Positive in PFS; Improved ORR.
Consistent findings summarised by Stephen L. Chan.
Tace better with systemic (aware of tox).
I would add that we must select patients to see who may be ‘just fine’ with sequential approach”
Other articles featuring Angela Lamarca on OncoDaily.
